,address1,address2,city,state,zip,country,phone,fax,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,pegRatio,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,55 Collins Street,Level 38,Melbourne,VIC,3000,Australia,61 3 9639 6036,61 3 9639 6030,https://www.mesoblast.com,Biotechnology,Healthcare,"Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.",83,"{'maxAge': 1, 'name': 'Dr. Silviu  Itescu FACP, FACRA, FRACP, MBBS (Hons)', 'age': 65, 'title': 'Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director', 'yearBorn': 1957, 'fiscalYear': 2023, 'totalPay': 1129866, 'exercisedValue': 0, 'unexercisedValue': 0}",7,6,10,10,9,1693526400,1703980800,86400,4,0.42,0.43,0.425,0.44,0.42,0.43,0.425,0.44,0.0,2.50075,-1.075,3906307,3906307,6741832,2791193,2791193,0.425,0.43,0,0,349874688,0.34,1.425,46.643738,0.7356,0.934875,0.0,0.0,AUD,419461472,0.0,675803183,813662016,0.17538,0.21113001,0.617,0.69692063,1688083200,1719705600,1688083200,-81889000,-0.16,-0.4,2.03,55.921,-6.275,ASX,EQUITY,MSB.AX,MSB.AX,MESOBLAST FPO,Mesoblast Limited,1103151600,Australia/Sydney,AEST,36000000,0.43,1.71,0.79,1.15,0.93,2.4,buy,3,71318000,0.088,-66843000,116495000,1.854,1.945,7501000,23.214,0.01,-0.06505,-0.16396,-47421000,-60159780,-63269000,-0.038,0.0,0.0,-9.2373,USD,
1,55 Collins Street,Level 38,Melbourne,VIC,3000,Australia,61 3 9639 6036,61 3 9639 6030,https://www.mesoblast.com,Biotechnology,Healthcare,"Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.",83,"{'maxAge': 1, 'name': 'Dr. Eric A. Rose M.D.', 'age': 71, 'title': 'Chief Medical Officer & Exec. Director', 'yearBorn': 1951, 'fiscalYear': 2023, 'totalPay': 956614, 'exercisedValue': 0, 'unexercisedValue': 0}",7,6,10,10,9,1693526400,1703980800,86400,4,0.42,0.43,0.425,0.44,0.42,0.43,0.425,0.44,0.0,2.50075,-1.075,3906307,3906307,6741832,2791193,2791193,0.425,0.43,0,0,349874688,0.34,1.425,46.643738,0.7356,0.934875,0.0,0.0,AUD,419461472,0.0,675803183,813662016,0.17538,0.21113001,0.617,0.69692063,1688083200,1719705600,1688083200,-81889000,-0.16,-0.4,2.03,55.921,-6.275,ASX,EQUITY,MSB.AX,MSB.AX,MESOBLAST FPO,Mesoblast Limited,1103151600,Australia/Sydney,AEST,36000000,0.43,1.71,0.79,1.15,0.93,2.4,buy,3,71318000,0.088,-66843000,116495000,1.854,1.945,7501000,23.214,0.01,-0.06505,-0.16396,-47421000,-60159780,-63269000,-0.038,0.0,0.0,-9.2373,USD,
2,55 Collins Street,Level 38,Melbourne,VIC,3000,Australia,61 3 9639 6036,61 3 9639 6030,https://www.mesoblast.com,Biotechnology,Healthcare,"Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.",83,"{'maxAge': 1, 'name': 'Dr. Philip R. Krause M.B.A., M.D., M.S.', 'title': 'Strategic Advisor & Director', 'fiscalYear': 2023, 'totalPay': 138497, 'exercisedValue': 0, 'unexercisedValue': 0}",7,6,10,10,9,1693526400,1703980800,86400,4,0.42,0.43,0.425,0.44,0.42,0.43,0.425,0.44,0.0,2.50075,-1.075,3906307,3906307,6741832,2791193,2791193,0.425,0.43,0,0,349874688,0.34,1.425,46.643738,0.7356,0.934875,0.0,0.0,AUD,419461472,0.0,675803183,813662016,0.17538,0.21113001,0.617,0.69692063,1688083200,1719705600,1688083200,-81889000,-0.16,-0.4,2.03,55.921,-6.275,ASX,EQUITY,MSB.AX,MSB.AX,MESOBLAST FPO,Mesoblast Limited,1103151600,Australia/Sydney,AEST,36000000,0.43,1.71,0.79,1.15,0.93,2.4,buy,3,71318000,0.088,-66843000,116495000,1.854,1.945,7501000,23.214,0.01,-0.06505,-0.16396,-47421000,-60159780,-63269000,-0.038,0.0,0.0,-9.2373,USD,
3,55 Collins Street,Level 38,Melbourne,VIC,3000,Australia,61 3 9639 6036,61 3 9639 6030,https://www.mesoblast.com,Biotechnology,Healthcare,"Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.",83,"{'maxAge': 1, 'name': 'Mr. Andrew  Chaponnel B.Com.', 'title': 'Interim Chief Fin. Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",7,6,10,10,9,1693526400,1703980800,86400,4,0.42,0.43,0.425,0.44,0.42,0.43,0.425,0.44,0.0,2.50075,-1.075,3906307,3906307,6741832,2791193,2791193,0.425,0.43,0,0,349874688,0.34,1.425,46.643738,0.7356,0.934875,0.0,0.0,AUD,419461472,0.0,675803183,813662016,0.17538,0.21113001,0.617,0.69692063,1688083200,1719705600,1688083200,-81889000,-0.16,-0.4,2.03,55.921,-6.275,ASX,EQUITY,MSB.AX,MSB.AX,MESOBLAST FPO,Mesoblast Limited,1103151600,Australia/Sydney,AEST,36000000,0.43,1.71,0.79,1.15,0.93,2.4,buy,3,71318000,0.088,-66843000,116495000,1.854,1.945,7501000,23.214,0.01,-0.06505,-0.16396,-47421000,-60159780,-63269000,-0.038,0.0,0.0,-9.2373,USD,
4,55 Collins Street,Level 38,Melbourne,VIC,3000,Australia,61 3 9639 6036,61 3 9639 6030,https://www.mesoblast.com,Biotechnology,Healthcare,"Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.",83,"{'maxAge': 1, 'name': 'Ms. Dagmar  Rosa-Bjorkeson M.B.A., M.S.', 'age': 58, 'title': 'Chief Operating Officer', 'yearBorn': 1964, 'exercisedValue': 0, 'unexercisedValue': 0}",7,6,10,10,9,1693526400,1703980800,86400,4,0.42,0.43,0.425,0.44,0.42,0.43,0.425,0.44,0.0,2.50075,-1.075,3906307,3906307,6741832,2791193,2791193,0.425,0.43,0,0,349874688,0.34,1.425,46.643738,0.7356,0.934875,0.0,0.0,AUD,419461472,0.0,675803183,813662016,0.17538,0.21113001,0.617,0.69692063,1688083200,1719705600,1688083200,-81889000,-0.16,-0.4,2.03,55.921,-6.275,ASX,EQUITY,MSB.AX,MSB.AX,MESOBLAST FPO,Mesoblast Limited,1103151600,Australia/Sydney,AEST,36000000,0.43,1.71,0.79,1.15,0.93,2.4,buy,3,71318000,0.088,-66843000,116495000,1.854,1.945,7501000,23.214,0.01,-0.06505,-0.16396,-47421000,-60159780,-63269000,-0.038,0.0,0.0,-9.2373,USD,
5,55 Collins Street,Level 38,Melbourne,VIC,3000,Australia,61 3 9639 6036,61 3 9639 6030,https://www.mesoblast.com,Biotechnology,Healthcare,"Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.",83,"{'maxAge': 1, 'name': 'Mr. Peter T. Howard B.Sc., L.L.B., BSc, LLB (Hons)', 'age': 54, 'title': 'Gen. Counsel & Corp. Exec.', 'yearBorn': 1968, 'fiscalYear': 2021, 'exercisedValue': 0, 'unexercisedValue': 0}",7,6,10,10,9,1693526400,1703980800,86400,4,0.42,0.43,0.425,0.44,0.42,0.43,0.425,0.44,0.0,2.50075,-1.075,3906307,3906307,6741832,2791193,2791193,0.425,0.43,0,0,349874688,0.34,1.425,46.643738,0.7356,0.934875,0.0,0.0,AUD,419461472,0.0,675803183,813662016,0.17538,0.21113001,0.617,0.69692063,1688083200,1719705600,1688083200,-81889000,-0.16,-0.4,2.03,55.921,-6.275,ASX,EQUITY,MSB.AX,MSB.AX,MESOBLAST FPO,Mesoblast Limited,1103151600,Australia/Sydney,AEST,36000000,0.43,1.71,0.79,1.15,0.93,2.4,buy,3,71318000,0.088,-66843000,116495000,1.854,1.945,7501000,23.214,0.01,-0.06505,-0.16396,-47421000,-60159780,-63269000,-0.038,0.0,0.0,-9.2373,USD,
6,55 Collins Street,Level 38,Melbourne,VIC,3000,Australia,61 3 9639 6036,61 3 9639 6030,https://www.mesoblast.com,Biotechnology,Healthcare,"Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.",83,"{'maxAge': 1, 'name': 'Mr. Roger D. Brown BA', 'title': 'Head of Spinal Orthopedic Disorders', 'fiscalYear': 2018, 'exercisedValue': 0, 'unexercisedValue': 0}",7,6,10,10,9,1693526400,1703980800,86400,4,0.42,0.43,0.425,0.44,0.42,0.43,0.425,0.44,0.0,2.50075,-1.075,3906307,3906307,6741832,2791193,2791193,0.425,0.43,0,0,349874688,0.34,1.425,46.643738,0.7356,0.934875,0.0,0.0,AUD,419461472,0.0,675803183,813662016,0.17538,0.21113001,0.617,0.69692063,1688083200,1719705600,1688083200,-81889000,-0.16,-0.4,2.03,55.921,-6.275,ASX,EQUITY,MSB.AX,MSB.AX,MESOBLAST FPO,Mesoblast Limited,1103151600,Australia/Sydney,AEST,36000000,0.43,1.71,0.79,1.15,0.93,2.4,buy,3,71318000,0.088,-66843000,116495000,1.854,1.945,7501000,23.214,0.01,-0.06505,-0.16396,-47421000,-60159780,-63269000,-0.038,0.0,0.0,-9.2373,USD,
7,55 Collins Street,Level 38,Melbourne,VIC,3000,Australia,61 3 9639 6036,61 3 9639 6030,https://www.mesoblast.com,Biotechnology,Healthcare,"Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.",83,"{'maxAge': 1, 'name': 'Mr. Michael  Schuster M.B.A., MS, BSc, MBA', 'age': 45, 'title': 'Head of Pharma Partnering', 'yearBorn': 1977, 'fiscalYear': 2021, 'exercisedValue': 0, 'unexercisedValue': 0}",7,6,10,10,9,1693526400,1703980800,86400,4,0.42,0.43,0.425,0.44,0.42,0.43,0.425,0.44,0.0,2.50075,-1.075,3906307,3906307,6741832,2791193,2791193,0.425,0.43,0,0,349874688,0.34,1.425,46.643738,0.7356,0.934875,0.0,0.0,AUD,419461472,0.0,675803183,813662016,0.17538,0.21113001,0.617,0.69692063,1688083200,1719705600,1688083200,-81889000,-0.16,-0.4,2.03,55.921,-6.275,ASX,EQUITY,MSB.AX,MSB.AX,MESOBLAST FPO,Mesoblast Limited,1103151600,Australia/Sydney,AEST,36000000,0.43,1.71,0.79,1.15,0.93,2.4,buy,3,71318000,0.088,-66843000,116495000,1.854,1.945,7501000,23.214,0.01,-0.06505,-0.16396,-47421000,-60159780,-63269000,-0.038,0.0,0.0,-9.2373,USD,
8,55 Collins Street,Level 38,Melbourne,VIC,3000,Australia,61 3 9639 6036,61 3 9639 6030,https://www.mesoblast.com,Biotechnology,Healthcare,"Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.",83,"{'maxAge': 1, 'name': 'Ms. Geraldine  Storton B.Sc., M.B.A., Bsc, MMS, MBA', 'title': 'Head of Regulatory Affairs & Quality Management', 'fiscalYear': 2021, 'exercisedValue': 0, 'unexercisedValue': 0}",7,6,10,10,9,1693526400,1703980800,86400,4,0.42,0.43,0.425,0.44,0.42,0.43,0.425,0.44,0.0,2.50075,-1.075,3906307,3906307,6741832,2791193,2791193,0.425,0.43,0,0,349874688,0.34,1.425,46.643738,0.7356,0.934875,0.0,0.0,AUD,419461472,0.0,675803183,813662016,0.17538,0.21113001,0.617,0.69692063,1688083200,1719705600,1688083200,-81889000,-0.16,-0.4,2.03,55.921,-6.275,ASX,EQUITY,MSB.AX,MSB.AX,MESOBLAST FPO,Mesoblast Limited,1103151600,Australia/Sydney,AEST,36000000,0.43,1.71,0.79,1.15,0.93,2.4,buy,3,71318000,0.088,-66843000,116495000,1.854,1.945,7501000,23.214,0.01,-0.06505,-0.16396,-47421000,-60159780,-63269000,-0.038,0.0,0.0,-9.2373,USD,
9,55 Collins Street,Level 38,Melbourne,VIC,3000,Australia,61 3 9639 6036,61 3 9639 6030,https://www.mesoblast.com,Biotechnology,Healthcare,"Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.",83,"{'maxAge': 1, 'name': 'Mr. Justin  Horst B.S.', 'title': 'Head of Manufacturing', 'exercisedValue': 0, 'unexercisedValue': 0}",7,6,10,10,9,1693526400,1703980800,86400,4,0.42,0.43,0.425,0.44,0.42,0.43,0.425,0.44,0.0,2.50075,-1.075,3906307,3906307,6741832,2791193,2791193,0.425,0.43,0,0,349874688,0.34,1.425,46.643738,0.7356,0.934875,0.0,0.0,AUD,419461472,0.0,675803183,813662016,0.17538,0.21113001,0.617,0.69692063,1688083200,1719705600,1688083200,-81889000,-0.16,-0.4,2.03,55.921,-6.275,ASX,EQUITY,MSB.AX,MSB.AX,MESOBLAST FPO,Mesoblast Limited,1103151600,Australia/Sydney,AEST,36000000,0.43,1.71,0.79,1.15,0.93,2.4,buy,3,71318000,0.088,-66843000,116495000,1.854,1.945,7501000,23.214,0.01,-0.06505,-0.16396,-47421000,-60159780,-63269000,-0.038,0.0,0.0,-9.2373,USD,
